Date:		11/15/2021	11/15/2021		
Your Name: Manuscript Title:		Ye Su	Ye Su		
		Electrocardiographic findings over time and their prognostic value	ue in patients with COVID-19		
Ma	nuscript Number (if kr	nown): APM-21 -3188			
con affe indi The epic tha	tent of your manuscri ected by the content of cate a bias. If you are author's relationships demiology of hypertent t medication is not me	rency, we ask you to disclose all relationships/activities/interests listed belowipt. "Related" means any relation with for-profit or not-for-profit third part of the manuscript. Disclosure represents a commitment to transparency and in doubt about whether to list a relationship/activity/interest, it is preferables/activities/interests should be defined broadly. For example, if your manuscript, you should declare all relationships with manufacturers of antihypertentioned in the manuscript. all support for the work reported in this manuscript without time limit. For e past 36 months.	ties whose interests may be ad does not necessarily ble that you do so. Uscript pertains to the tensive medication, even if		
		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Com made to you or to you	nments (e.g., if payments were your institution)		
		Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by the fundamental Research Funds for the central Universities Grant Number: ZYGX2020ZB038 This work was supported by Sichuan provincial department of science and technology project Grant Number: 2018JY0649, 2020YFS0404 Click the tab key to add acceptable of the fundamental Research Fundamental R	dditional rows.		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This work was supported by the fundamental Research Funds for the central Universities Grant Number: ZYGX2020ZB038 This work was supported by Sichuan provincial department of science and technology project Grant Number: 2018JY0649, 2020YFS0404	dditional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This work was supported by the fundamental Research Funds for the central Universities Grant Number: ZYGX2020ZB038 This work was supported by Sichuan provincial department of science and technology project Grant Number: 2018JY0649, 2020YFS0404 Click the tab key to add according to the fundamental Research Fundamental Research Fundamental Universities Grant Number: ZYGX2020ZB038 This work was supported by Sichuan provincial department of science and technology project Grant Number: 2018JY0649, 2020YFS0404	dditional rows.		

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None — — — — — — — — — — — — — — — — — — —
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None — — — — — — — — — — — — — — — — — — —

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	•	e following statement to indicate your agreeme	

Date:			11/15/2021			
Your Name:			LIXue Yin			
Manuscript Title:			Electrocardiographic findings over time and their prognostic value in patients with COVID-19			
Ma	nuscript Number (if k	known):	APM-21 -3188			
content of your manuscript. "Rela affected by the content of the mai indicate a bias. If you are in doubt The author's relationships/activitic epidemiology of hypertension, you that medication is not mentioned			nted" means any relation with for-profit or no nuscript. Disclosure represents a commitment about whether to list a relationship/activity, es/interests should be defined broadly. For each as should declare all relationships with manufain the manuscript.	/interest, it is preferable that you do so.		
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This was Research Grant Market Washington	ork was supported by the fundamental ch Funds for the central Universities Number: ZYGX2020ZB038 ork was supported by Sichuan provincial nent of science and technology project Number: 2018JY0649, 2020YFS0404	Click the tab key to add additional rows.		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This was Research Grant Market Washington	ork was supported by the fundamental ch Funds for the central Universities Number: ZYGX2020ZB038 ork was supported by Sichuan provincial nent of science and technology project			
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This was Research Grant Market Washington	ork was supported by the fundamental ch Funds for the central Universities Number: ZYGX2020ZB038 ork was supported by Sichuan provincial ment of science and technology project Number: 2018JY0649, 2020YFS0404 Time frame: past 36 month			

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None — — — — — — — — — — — — — — — — — — —
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None — — — — — — — — — — — — — — — — — — —

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	•	e following statement to indicate your agreeme	

Date:			11/15/2021			
Your Name:			Jun Lin			
Manuscript Title:			Electrocardiographic findings over time and their prognostic value in patients with COVID-19			
Mar	nuscript Number (if k	nown):	APM-21 -3188			
content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub." The author's relationships/activiti- epidemiology of hypertension, you that medication is not mentioned			nted" means any relation with for-profit or no nuscript. Disclosure represents a commitment about whether to list a relationship/activity, es/interests should be defined broadly. For e u should declare all relationships with manufa- in the manuscript.	/interest, it is preferable that you do so.		
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1	All support for the present manuscript (e.g., funding, provision	This we	ork was supported by the fundamental			
	of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Grant N This we departm	ch Funds for the central Universities Number: ZYGX2020ZB038 ork was supported by Sichuan provincial ment of science and technology project Number: 2018JY0649, 2020YFS0404	Click the tab key to add additional rows.		
	of study materials, medical writing, article processing charges, etc.) No time limit for	Grant N This we departm	Number: ZYGX2020ZB038 ork was supported by Sichuan provincial nent of science and technology project			
2	of study materials, medical writing, article processing charges, etc.) No time limit for	Grant N This we departm	Number: ZYGX2020ZB038 ork was supported by Sichuan provincial ment of science and technology project Number: 2018JY0649, 2020YFS0404 Time frame: past 36 month			

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None — — — — — — — — — — — — — — — — — — —
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None — — — — — — — — — — — — — — — — — — —

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	•	e following statement to indicate your agreeme	

Date:		_	11/15/2021			
Your Name:		_	QiongHui Peng			
Manuscript Title:		_	Electrocardiographic findings over time and their prognostic value in patients with COVID-19			
Ma	nuscript Number (if kr	nown):	APM-21 -3188			
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub! The author's relationships/activitic epidemiology of hypertension, you that medication is not mentioned			ted" means any relation with for-profit or no nuscript. Disclosure represents a commitmen about whether to list a relationship/activity, es/interests should be defined broadly. For each should declare all relationships with manufaction the manuscript.	/interest, it is preferable that you do so.		
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time forms. Cinca the initial planning			
			Time frame: Since the initial planning	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Research Grant N This woodepartm		Click the tab key to add additional rows.		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This wo	by the fundamental h Funds for the central Universities Sumber: ZYGX2020ZB038 by was supported by Sichuan provincial ment of science and technology project	Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This wo	one ork was supported by the fundamental h Funds for the central Universities Jumber: ZYGX2020ZB038 ork was supported by Sichuan provincial ment of science and technology project fumber: 2018JY0649, 2020YFS0404 Time frame: past 36 month	Click the tab key to add additional rows.		

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None — — — — — — — — — — — — — — — — — — —
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None — — — — — — — — — — — — — — — — — — —

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	•	e following statement to indicate your agreeme	

Date:			11/15/2021		
Your Name:			RuiShi		
Manuscript Title:			Electrocardiographic findings over time and their prognostic value in patients with COVID-19		
Manuscript Number (if known):			APM-21 -3188		
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the maindicate a bias. If you are in doubt. The author's relationships/activitic epidemiology of hypertension, you that medication is not mentioned."			ated" means any relation with for-profit or no nuscript. Disclosure represents a commitment t about whether to list a relationship/activity, es/interests should be defined broadly. For e u should declare all relationships with manufa- in the manuscript.	/interest, it is preferable that you do so.	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This we Research This we departn	ork was supported by the fundamental ch Funds for the central Universities Number: ZYGX2020ZB038 ork was supported by Sichuan provincial nent of science and technology project Number: 2018JY0649, 2020YFS0404	Click the tab key to add additional rows.	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This we Research This we departn	cork was supported by the fundamental ch Funds for the central Universities Number: ZYGX2020ZB038 cork was supported by Sichuan provincial ment of science and technology project		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This we Research This we departn	ork was supported by the fundamental ch Funds for the central Universities Number: ZYGX2020ZB038 ork was supported by Sichuan provincial nent of science and technology project Number: 2018JY0649, 2020YFS0404 Time frame: past 36 month		

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None None
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options		None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None		
13	Other financial or non-financial interests		None		
Plea	Please place an "X" next to the following statement to indicate your agreement:				

Date:		·-	11/15/2021			
Your Name:		-	NaDaZhu			
Manuscript Title:		-	Electrocardiographic findings over time and their prognostic value in patients with COVID-19			
Manuscript Number (if known):		(nown):	APM-21 -3188			
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the maindicate a bias. If you are in doubt. The author's relationships/activitic epidemiology of hypertension, you that medication is not mentioned."			ted" means any relation with for-profit or no nuscript. Disclosure represents a commitment about whether to list a relationship/activity, es/interests should be defined broadly. For each should declare all relationships with manufain the manuscript.	/interest, it is preferable that you do so.		
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
			8	or the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This we Grant N This we departm	ork was supported by the fundamental ch Funds for the central Universities Number: ZYGX2020ZB038 ork was supported by Sichuan provincial nent of science and technology project Number: 2018JY0649, 2020YFS0404	Click the tab key to add additional rows.		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This we Grant N This we departm	one ork was supported by the fundamental the Funds for the central Universities Number: ZYGX2020ZB038 ork was supported by Sichuan provincial the provincial the provincial that of science and technology project	Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This we Grant N This we departm	one ork was supported by the fundamental the Funds for the central Universities Number: ZYGX2020ZB038 ork was supported by Sichuan provincial ment of science and technology project Number: 2018JY0649, 2020YFS0404 Time frame: past 36 month	Click the tab key to add additional rows.		

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None None
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options		None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None		
13	Other financial or non-financial interests		None		
Plea	Please place an "X" next to the following statement to indicate your agreement:				

Date:		_1	11/15/2021		
Your Name:		<u>H</u>	HuangXing Li		
Manuscript Title:		_ <u>E</u>	Electrocardiographic findings over time and their prognostic value in patients with COVID-19		
Manuscript Number (if known):		nown): <u>A</u>	PM-21 -3188		
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub! The author's relationships/activitic epidemiology of hypertension, you that medication is not mentioned			d" means any relation with for-profit or no script. Disclosure represents a commitme bout whether to list a relationship/activity interests should be defined broadly. For each ould declare all relationships with manufathe manuscript.	es/interests listed below that are related to the ot-for-profit third parties whose interests may be not to transparency and does not necessarily /interest, it is preferable that you do so. example, if your manuscript pertains to the acturers of antihypertensive medication, even if without time limit. For all other items, the time	
			ntities with whom you have this p or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame. Cines the initial planning	-Calconnell	
			Time frame: Since the initial planning	of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Research I Grant Nur This work departmen		Click the tab key to add additional rows.	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This work Research I Grant Nur This work department	k was supported by the fundamental Funds for the central Universities mber: ZYGX2020ZB038 k was supported by Sichuan provincial at of science and technology project	Click the tab key to add additional rows.	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This work Research I Grant Nur This work department	k was supported by the fundamental Funds for the central Universities mber: ZYGX2020ZB038 k was supported by Sichuan provincial at of science and technology project mber: 2018JY0649, 2020YFS0404	Click the tab key to add additional rows.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None None
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options		None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None		
13	Other financial or non-financial interests		None		
Plea	Please place an "X" next to the following statement to indicate your agreement:				